NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Soligenix, Inc. SNGX
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-2.14
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-235.5%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -2.14
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-235.5%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-121.7%
Each USD of equity lost 235 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−51.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−47.5%
−51.9%
−33.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 9.2M
total assets, end of FY2025
Total assetsUSD 9.2M
EquityUSD 5.3M
CashUSD 7.9M
Current ratio2.39×
Equity funds 57% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.14
−4.98
−12.66
−4.81
−4.69
−0.64
−0.48
−0.68
−1.16
−1.34
−3.00
−0.43
−0.65
−0.37
−0.22
−0.73
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−235.5
−249.0
−23803.1
−334.4
−173.5
−680.5
−241.8
−141.3
−104.2
−88.0
·
·
−1129.4
−80.5
−33.6
−100.4
Shares out B
0.01
0.00
0.00
0.00
0.00
0.03
0.02
0.02
0.01
0.01
0.00
0.02
0.02
0.01
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
61 of 61
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed